Carl Stefan Fraenkel
Directeur/Bestuurslid bij Akinion Pharmaceuticals AB
Actieve functies van Carl Stefan Fraenkel
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Directeur/Bestuurslid | - | - |
Loopbaan van Carl Stefan Fraenkel
Eerdere bekende functies van Carl Stefan Fraenkel
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 23-02-2011 | - |
Opleiding van Carl Stefan Fraenkel
| Copenhagen Business School | Doctorate Degree |
| Chalmers University of Technology | Undergraduate Degree |
Statistieken
Internationaal
| Zweden | 4 |
| Denemarken | 2 |
Operationeel
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
